Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- METI Report Calls For Free Competition for Medical, Nursing Care Services
February 26, 2001
- BUSINESS NEWS IN BRIEF -1-
February 26, 2001
- Elimination of NHI Price SystemShould Be Considered: Prof. Tokita
February 26, 2001
- REGULATORY NEWS IN BRIEF
February 26, 2001
- WORLD BUSINESS NEWS IN BRIEF
February 26, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 26, 2001
- New Law Specific for Medical Devices Is Necessary: JFITMA President
February 26, 2001
- Kirin to Sponsor Genomic Medical Engineering Course at Tottori Univ.
February 26, 2001
- New ARIA Guidelines Prepared by WHO for Allergic Rhinitis
February 26, 2001
- Big Internet Influence on Pharma Fields Predicted: Mr Tanimura of So-net M3
February 26, 2001
- Strategies of AdvaMed, EUCOMED for Japan Revealed
February 26, 2001
- Suzuken to Quit Nursing Home Business
February 26, 2001
- OTC NEWS IN BRIEF
February 26, 2001
- BUSINESS NEWS IN BRIEF -2-
February 26, 2001
- Sysmex Expands Its Development Base in Europe
February 26, 2001
- Chuikyo Subcommittee Starts Discussions on Drug Prices
February 26, 2001
- Reorganization to Push New Drugs into Orbit as Soon as Possible: Mr Nakashima of Tanabe
February 26, 2001
- Chugai's '75-year History' Published
February 19, 2001
- Standard Drug Name, Lab Test Masters Completed
February 19, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
February 19, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…